Target intelligence / Profile preview

Solute carrier family 2, facilitated glucose transporter member 9 (GLUT9)

Target
GLUT9
Molecular classification
Transporter
01

Overview

Solute carrier family 2, facilitated glucose transporter member 9 (SLC2A9), commonly known as GLUT9, is a voltage-sensitive, high-capacity urate transporter primarily expressed in the kidneys, liver, and intestine. Although structurally related to the facilitative glucose transporter family, its primary physiological substrate is uric acid (urate), which it transports at rates significantly faster than hexoses. GLUT9 plays a critical role in maintaining systemic uric acid homeostasis by mediating the reabsorption of urate from the renal proximal tubules back into the bloodstream. Dysregulation or genetic variations in SLC2A9 are strongly associated with hyperuricemia, gout, and nephrolithiasis, while loss-of-function mutations cause hereditary renal hypouricemia type 2, which predisposes individuals to exercise-induced acute kidney injury. Consequently, GLUT9 is a major therapeutic target for uricosuric drugs designed to lower serum uric acid levels in patients with gout and hyperuricemia. Pharmacological inhibitors of GLUT9, including traditional uricosuric agents like benzbromarone and probenecid, as well as novel selective inhibitors like JTT-763, block urate reabsorption to promote urinary excretion, though therapeutic development must carefully balance efficacy with the risk of renal stones and acute kidney injury.

Other names
SLC2A9GLUT-9Glucose transporter type 9Urate transporterUrate voltage-driven efflux transporter 1URATv1
02

Mechanism of action

Inhibition of SLC2A9/GLUT9-mediated urate transport to block renal reabsorption and promote urinary excretion of uric acid

03

Biological functions

Urate transportGlucose transportFructose transportUric acid homeostasisAntioxidant defense
04

Disease associations

GoutHyperuricemiaRenal hypouricemia type 2NephrolithiasisChronic kidney diseaseCardiovascular diseaseHypertension
05

Safety considerations

Renal hypouricemiaExercise-induced acute renal failureNephrolithiasisUrate nephropathyOff-target effects on glucose or fructose transport
06

Interacting drugs

7 more in the full profile.

07

Biomarkers

Serum uric acid levelsUrinary uric acid levelsSLC2A9 gene polymorphisms

Beyond the preview

Go deeper on Solute carrier family 2, facilitated glucose transporter member 9 (GLUT9).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Solute carrier family 2, facilitated glucose transporter member 9 (GLUT9).

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call